Loading organizations...
§ Private Profile · Hong Kong, China
Develops genome editing technologies and delivery platforms for in vivo gene therapies treating genetic diseases.
GenEditBio is a biotechnology company based in Pak Shek Kok, Hong Kong, that develops next-generation genome editing technologies and delivery platforms for in vivo therapies targeting genetic diseases. The enterprise focuses on creating precise DNA surgery solutions designed to replace lifelong medical treatments with single-dose gene therapies, operating additional laboratory and office facilities in Beijing and Boston. To support its clinical pipeline and technological advancement, the startup has raised significant capital, including a $90 million funding round in 2024 alongside tens of millions of dollars in earlier angel and pre-Series A financing rounds. The biotechnology firm is backed by strategic venture capital investors such as Gobi Partners GBA and collaborates with prominent scientific researchers like J. Keith Joung on analytical technologies including GUIDE-seq. GenEditBio was founded in 2021 by Zongli Zheng and Tian Zhu.
GenEditBio has raised $90.0M across 1 funding round.
GenEditBio has raised $90.0M in total across 1 funding round.
GenEditBio has raised $90.0M in total across 1 funding round.
GenEditBio's investors include Lin Rongjin, Shuntian Pharmaceutical, Qiming Venture Partners, Hong Kong Science and Technology Parks Corporation.
GenEditBio has raised $90.0M across 1 funding round. Most recently, it raised $90.0M Seed in April 2024.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Apr 1, 2024 | $90M Seed | LIN Rongjin, Shuntian Pharmaceutical | Qiming Venture Partners, Hong Kong Science And Technology Parks Corporation | Announced |
GenEditBio is a clinical-stage biotechnology startup founded in 2021 and headquartered in Hong Kong, specializing in CRISPR-based precision genome editing for in vivo gene therapies targeting genetic diseases with unmet needs.[1][3][4][6] The company develops "DNA surgery" solutions—potentially curative, one-time interventions—using novel Cas nucleases and advanced delivery platforms like lipid nanoparticles (LNPs) and protein delivery vehicles (PDVs) to enable safe, efficient editing directly in the body.[3][4][6] It serves patients with conditions such as hereditary eye diseases, liver diseases, metabolic disorders, rare diseases, and atherosclerotic cardiovascular disease (ASCVD), addressing challenges like off-target effects, delivery precision, and durability in current therapies.[1][2][3][5][6] With ~20 employees, labs in Hong Kong, Beijing, and Boston, and backing from investors like Qiming Venture Partners and Gobi Partners, GenEditBio shows strong growth through preclinical advancements, a pipeline of five programs (including GEB-200 for ASCVD), and recent strategic partnerships.[1][3][5][6]
GenEditBio was founded in 2021 by co-founders Zongli Zheng, PhD (Chairman), who brings pioneering expertise from Boston in technologies like GUIDE-seq and delivery tools, and Tian Zhu, PhD (CEO), with deep experience in genome editing and business development.[2][3][4] The idea emerged from frustrations with existing in vivo gene therapies' limitations in targeted delivery, safety, and precision, particularly off-target effects and inefficiencies in addressing diverse genetic mutations.[1][2] Early traction came via top-tier funding from life science investors and rapid preclinical progress, including high-safety PDV data for ocular diseases in non-human primates, positioning the company as a leader in protein-based editing platforms.[3] This Hong Kong-based startup quickly expanded with global labs and a cross-license deal with ToolGen in 2025, accelerating its pipeline.[6]
GenEditBio stands out in the gene editing field through these key strengths:
GenEditBio rides the explosive growth of in vivo CRISPR therapeutics, fueled by regulatory wins like Casgevy and surging demand for one-time genetic cures amid aging populations and rising genetic disease prevalence.[2][4][6] Timing is ideal post-2020s CRISPR breakthroughs, as market forces favor safer delivery over nucleic acid risks, with GenEditBio's PDV/LNP innovations tackling key bottlenecks in precision and accessibility.[1][3] It influences the ecosystem by partnering globally (e.g., ToolGen cross-license), seeking pharma/academic alliances, and expanding from preclinical to clinical trials, potentially democratizing "DNA surgery" for underserved diseases like corneal dystrophy and ASCVD.[3][6] In Asia's biotech hub (Hong Kong), it bridges U.S. innovation with efficient scaling, contributing to a projected $20B+ gene editing market by 2030.[2][4]
GenEditBio is poised for breakthroughs with IND filings imminent for ocular and ASCVD programs, leveraging PDV's superior preclinical data to enter trials amid favorable volatility in CRISPR funding.[2][3][6] Trends like protein editors, LNP maturation, and AI-optimized nucleases will amplify its edge, while partnerships accelerate global reach and affordability.[3][6] Its influence may evolve from platform innovator to multi-disease leader, delivering transformative, equitable gene therapies that redefine treatment paradigms—echoing its founding mission of potent, safe "DNA surgery" for millions.[1][2][4]